Comparing ICD shock ratios between Type 1, Type 2 and non diabetic patients

Objective: The use of permanent pacemakers and implantable cardioverter defibrillators (ICDs) is increasing. With technological advances, the devices' implantation techniques and programmable features are improving, and indications are expanding. Several technical and clinical problems are encountered during implantation and follow-up of these devices. Methods: Our study retrospectively evaluated diabetic and non-diabetic patients who underwent ICD implantation in Mersin University Cardiology Department between January 2010 and December 2013 according to current indications. All clinical characteristics, baseline, 1-month and 6-month follow-up pacemaker data and baseline laboratory values were recorded. Results: A total of 106 ICD patients (57 diabetics and 49 nondiabetics) were enrolled at the 1st and 6th months of follow-up. 47.2% of the patients were male and the mean age was 56±7.3 years. ICDs were implanted for secondary prevention in 83.9% of patients. ICD was implanted for coronary artery disease +/- ventricular tachycardia (VT) or ventricular fibrillation (VF)+/- synchronization disorder. 75.4% of patients had CAD, and 89.6% had heart failure. The mean ejection fraction ratio (EF) was 31.3%. Early complications were observed in 10.3% of patients. 47.1% of patients received any treatment by the ICD, 34.9% had the appropriate shock, and 12.2% had inappropriate shock. The complication rate was 10.3%. While there was no difference in ventricular impedance and threshold values in diabetic patients compared to the control group, ventricular lead R amplitude values were found to be higher. The rate of atrial fibrillation was significantly different in the treated group. Treatment response was obtained in 71.4% of patients who underwent treatment change due to appropriate shock, incorrect shock and ATP. Conclusion: In conclusion, the incidence of appropriate shock and anti-tachycardic pacing was higher in diabetic patients than non-diabetic patients.

[1]  K. Poh,et al.  Diabetes mellitus and heart disease. , 2013, Singapore medical journal.

[2]  M. Kroll,et al.  Implantable Cardioverter Defibrillator Therapy: The Engineering-Clinical Interface , 2012, Developments in Cardiovascular Medicine.

[3]  H. Schelbert.  Coronary circulatory function abnormalities in insulin resistance: insights from positron emission tomography. , 2009, Journal of the American College of Cardiology.

[4]  Thomas Kleemann,et al.  Annual Rate of Transvenous Defibrillation Lead Defects in Implantable Cardioverter-Defibrillators Over a Period of >10 Years , 2007, Circulation.

[5]  M. Schoenfeld.  Contemporary Pacemaker and Defibrillator Device Therapy: Challenges Confronting the General Cardiologist , 2007, Circulation.

[6]  A. Vinik,et al.  Diabetic Cardiovascular Autonomic Neuropathy , 2007, Circulation.

[7]  E. Fain,et al.  Comparison of (cid:1) -Blockers, Amiodarone Plus (cid:1) -Blockers, or Sotalol for Prevention of Shocks From Implantable Cardioverter Defibrillators The OPTIC Study: A Randomized Trial , 2005 .

[8]  M. Movahed,et al.  Increased prevalence of third-degree atrioventricular block in patients with type II diabetes mellitus. , 2005, Chest.

[9]  P. Poole‐Wilson,et al.  Haemoglobin predicts survival in patients with chronic heart failure: a substudy of the ELITE II trial. , 2004, European heart journal.

[10]  D. Coursin,et al.  Assessment and therapy of selected endocrine disorders. , 2004, Anesthesiology clinics of North America.

[11]  L. Fananapazir,et al.  Efficacy of Implantable Cardioverter Defibrillator Therapy for Primary and Secondary Prevention of Sudden Cardiac Death in Hypertrophic Cardiomyopathy , 2003, Pacing and clinical electrophysiology : PACE.

[12]  F. Morady,et al.  Amiodarone versus implantable cardioverter-defibrillator:randomized trial in patients with nonischemic dilated cardiomyopathy and asymptomatic nonsustained ventricular tachycardia--AMIOVIRT. , 2003, Journal of the American College of Cardiology.

[13]  David O. Martin,et al.  Dual-chamber pacing or ventricular backup pacing in patients with an implantable defibrillator: the Dual Chamber and VVI Implantable Defibrillator (DAVID) Trial. , 2002, JAMA.

[14]  H. King,et al.  Population-based study of diabetes and risk characteristics in Turkey: results of the turkish diabetes epidemiology study (TURDEP). , 2002, Diabetes care.

[15]  G. Breithardt,et al.  Consensus Statement on Indications, Guidelines for Use, and Recommendations for Follow‐up of Implantable Cardioverter Defibrillators , 2001, Pacing and clinical electrophysiology : PACE.

[16]  S. Connolly,et al.  Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. AVID, CASH and CIDS studies. Antiarrhythmics vs Implantable Defibrillator study. Cardiac Arrest Study Hamburg . Canadian Implantable Defibrillator Study. , 2000, European heart journal.

[17]  A J Moss,et al.  Implantable cardioverter defibrillator therapy: the sickest patients benefit the most. , 2000, Circulation.

[18]  H. King,et al.  Global Burden of Diabetes, 1995–2025: Prevalence, numerical estimates, and projections , 1998, Diabetes Care.

[19]  M. Keller,et al.  A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. , 1997, The New England journal of medicine.

[20]  M. Block,et al.  [Results of testing defibrillator function of implanted cardioverter/defibrillators]. , 1997, Zeitschrift für Kardiologie.

[21]  M. Stanton,et al.  Transtelephonic Monitoring and Transmission of Stored Arrhythmia Detection and Therapy Data From an Implantable Cardioverter Defibrillator , 1995, Pacing and clinical electrophysiology : PACE.

[22]  J. Elefteriades,et al.  Ventricular arrhythmias in heart failure. , 1995, Cardiology clinics.

[23]  H. Trappe,et al.  Role of Antitachycardia Pacing in Patients with Third Generation Cardioverter Defibrillators , 1994, Pacing and clinical electrophysiology : PACE.

[24]  F. Marchlinski,et al.  Shock Occurrence and Survival in 241 Patients With Implantable Cardioverter‐ Defibrillator Therapy , 1993, Circulation.

[25]  R. Wolfe,et al.  Predictive survival models for resuscitated victims of out-of-hospital cardiac arrest with coronary heart disease. , 1985, Circulation.

[26]  M. Josephson,et al.  Prognostic factors in nonsustained ventricular tachycardia. , 1984, The American journal of cardiology.

[27]  V L Gott,et al.  Termination of malignant ventricular arrhythmias with an implanted automatic defibrillator in human beings. , 1980, The New England journal of medicine.

[28]  L. Cobb,et al.  Resuscitation From Out‐of‐Hospital Ventricular Fibrillation: 4 Years Follow‐up , 1975, Circulation.

[29]  M. Mirowski,et al.  Transvenous automatic defibrillator as an approach to prevention of sudden death from ventricular fibrillation. , 1973, Heart & lung : the journal of critical care.

[30]  P. Zoll,et al.  Resuscitation of the heart in ventricular standstill by external electric stimulation. , 1952, The New England journal of medicine.

[31]  R. Piotrowicz,et al.  Remote monitoring of implantable cardioverter defibrillators. , 2014, Hellenic journal of cardiology : HJC = Hellenike kardiologike epitheorese.

[32]  P. Keeling,et al.  The dinoflagellates Durinskia baltica and Kryptoperidinium foliaceum retain functionally overlapping mitochondria from two evolutionarily distinct lineages , 2007, BMC Evolutionary Biology.

[33]  H. Katus,et al.  What is the "optimal" follow-up schedule for ICD patients? , 2005, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[34]  J F Leclercq,et al.  Ambulatory sudden cardiac death: mechanisms of production of fatal arrhythmia on the basis of data from 157 cases. , 1989, American heart journal.